Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar 20;8(20):11014-11020.
doi: 10.1039/c8ra00661j. eCollection 2018 Mar 16.

Shape and structure controlling of calcium oxalate crystals by a combination of additives in the process of biomineralization

Affiliations

Shape and structure controlling of calcium oxalate crystals by a combination of additives in the process of biomineralization

Nian Liu et al. RSC Adv. .

Abstract

The origin of complex hierarchical superstructures of biomaterials and their unique self-assembly mechanisms of formation are important in biological systems and have attracted considerable attention. In the present study, we investigated the morphological changes of calcium oxalate (CaO x ) crystals induced by additives including chiral aspartic acid, sodium citrate, Mg2+, casein and combinations of these molecules. The morphology and structure of CaO x were identified with the use of various techniques. The morphogenesis of CaO x crystals were significantly affected by chiral aspartic acid, sodium citrate or Mg2+. However, they only formed calcium oxalate monohydrate (COM). It was observed that the chiral aspartic acid, sodium citrate and casein adhered to the surface of the crystals. The adherence of Mg2+ to crystals was not evident. Casein significantly affected the formation of COM and calcium oxalate dihydrate (COD). The ratio of different CaO x crystal forms is associated with the casein concentration. In combination with Mg2+ or citrate ions, casein showed improved formation of COD. The present study mimics biomineralization with a simple chemical approach and provides insight into the complicated system of CaO x biomineralization as well as facilitates the understanding of urinary stone treatment.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts to declare.

Figures

Fig. 1
Fig. 1. XRD results of COM acquired with or without the presence of small molecular additives at pH 6. The additive concentration in solution was 2 mmol L−1 for chiral aspartic acid or Mg2+, and 1 mmol L−1 for Na3 Citrate.
Fig. 2
Fig. 2. SEM images of COM formed in the presence of 20 mmol L−1 of d-aspartic acid (A1, A2) or l-aspartic acid (B1, B2). The pH solution was pH6 (A1, B1) and pH7 (A2, B2).
Fig. 3
Fig. 3. SEM images show the change of CaOx crystallization time form 0.5 day to 3 days. (A) CaOx, (B) CaOx with d-aspartic acid, (C) CaOx with l-aspartic acid, (D) CaOx with Mg2+, (E) CaOx with Na3 Citrate. 1 to 2 refers to 0.5 day and 3 days, separately.
Fig. 4
Fig. 4. CaOx formed within different concentration of casein in solution. (A) 0.1 g L−1, (B) 0.2 g L−1, (C) 0.4 g L−1, (D) 0.8 g L−1, (E) 2 g L−1, (F) 4 g L−1. 1 is the overview, 2 is magnification of 1 to show the crystal surface, 3 is magnification of 1 also to show the cross section.
Fig. 5
Fig. 5. XRD results illustrate changing from COM to COD formed with different concentration of casein.
Fig. 6
Fig. 6. COD formed with casein and small molecular additives. (A) 0.1 g L−1 casein + 2 mmol L−1 Mg2+, (B) 0.2 g L−1 casein + 2 mmol L−1 Mg2+, (C) 0.1 g L−1 casein + 1 mmol L−1 Na3 Citrate, (D) 0.2 g L−1 casein + 1 mmol L−1 Na3 Citrate. (E) XRD spectra of COD formed with additives.
Fig. 7
Fig. 7. XPS survey scan for CaOx crystals formed within different additives in solution (A) CaOx, (B) 0.2 g L−1 casein, (C) 0.2 g L−1 casein + 2 mmol L−1 Mg2+, (D) 0.2 g L−1 casein + 1 mmol L−1 Na3 Citrate.
Fig. 8
Fig. 8. FTIR results illustrate the influence of additives on CaOx.
Fig. 9
Fig. 9. FTIR results imply interactions between additives and CaOx.

References

    1. Turney B. W. Reynard J. M. Noble J. G. Keoghane S. R. BJU Int. 2012;109:1082–1087. doi: 10.1111/j.1464-410X.2011.10495.x. - DOI - PubMed
    1. Narula S. Tandon S. Singh S. K. Tandon C. Life Sci. 2016;164:23–30. doi: 10.1016/j.lfs.2016.08.026. - DOI - PubMed
    1. Zhao Z. Xia Y. Xue J. Wu Q. Cryst. Growth Des. 2014;14:450–458.
    1. Strope S. A. Wolf J. S. Hollenbeck B. K. Urology. 2010;75:543–546. doi: 10.1016/j.urology.2009.08.007. - DOI - PMC - PubMed
    1. Li H. Yao Q.-Z. Wang Y.-Y. Li Y.-L. Zhou G.-T. Sci. Rep. 2015;5:7718. doi: 10.1038/srep07718. - DOI - PMC - PubMed